Neurons expressing metabotropic glutamate receptor 3 (mGluR3/GRM3), a group II metabotropic glutamate receptor with both neuronal and glial expression patterns. GRM3 is a G protein-coupled receptor that primarily signals through Gi/o proteins, inhibiting adenylate cyclase and reducing cAMP production. This receptor plays crucial roles in regulating glutamatergic neurotransmission, synaptic plasticity, and neuroprotection throughout the central nervous system.
GRM3 is widely expressed across multiple brain regions:
- Cerebral Cortex: Layer-specific expression in pyramidal neurons, particularly in layers II/III and V
- Hippocampus: Predominant expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Basal Ganglia: Moderate expression in striatal medium spiny neurons
- Thalamus: Expression in relay neurons of various thalamic nuclei
- Cerebellum: Present in Purkinje cells and granule cells
- Substantia Nigra: Expression in dopaminergic neurons of the pars compacta
mGluR3 is found on both presynaptic and postsynaptic elements:
- Presynaptic: Located on axon terminals where it acts as an autoreceptor modulating glutamate release
- Postsynaptic: Located on dendritic spines and shafts regulating neuronal excitability
- Glial: Strong expression on astrocytes and oligodendrocyte precursor cells
GRM3 encodes a 879-amino acid protein belonging to class C metabotropic glutamate receptors:
- Large extracellular Venus flytrap domain (VFT) for glutamate binding
- Cysteine-rich domain linking VFT to transmembrane domains
- Seven transmembrane domains typical of GPCRs
- Intracellular C-terminal tail involved in protein interactions and signaling
mGluR3 activates multiple intracellular signaling cascades:
-
Gi/o Protein Signaling
- Inhibition of adenylate cyclase → reduced cAMP
- Activation of GIRK channels → hyperpolarization
- Inhibition of voltage-gated calcium channels
-
ERK/MAPK Pathway
- Activation of Ras-RAF-MEK-ERK cascade
- Involved in long-term synaptic changes
-
PI3K/Akt Pathway
- Neuroprotective signaling
- Regulation of cell survival
-
PLC-independent signaling
- Regulation of ion channel function
- Modulation of neurotransmitter release
Neurons expressing mGluR3 exhibit distinct electrophysiological characteristics:
- Resting membrane potential: Approximately -70 mV
- Input resistance: High due to Gi/o protein coupling
- Action potential threshold: Moderately elevated compared to other mGluRs
- Synaptic responses: mGluR3 activation produces slow inhibitory postsynaptic potentials
mGluR3 plays a complex role in synaptic plasticity:
- Long-term depression (LTD): Facilitates NMDA receptor-dependent LTD
- Long-term potentiation (LTP): Modulates LTP induction threshold
- Homeostatic plasticity: Regulates synaptic scaling in response to activity changes
GRM3-expressing neurons receive inputs from:
- Corticocortical pyramidal neurons
- Thalamocortical relay neurons
- Cholinergic neurons from basal forebrain
- Serotonergic neurons from raphe nuclei
- Noradrenergic neurons from locus coeruleus
These neurons project to:
- Local cortical circuits (intrinsic)
- Hippamp;ampal CA3 region via mossy fibers
- Subcortical structures including striatum and thalamus
- Contralateral cortical areas via corpus callosum
GRM3 has emerging relevance in Alzheimer's disease pathogenesis:
- Glutamate homeostasis: Dysregulated glutamate signaling contributes to excitotoxicity
- Amyloid interaction: APP processing may be modulated by mGluR3 signaling
- Tau pathology: Altered mGluR3 signaling may influence tau phosphorylation
- Cognitive function: Genetic variants in GRM3 associated with cognitive decline
- Therapeutic potential: mGluR3 modulators may have neuroprotective effects
In Parkinson's disease, GRM3-expressing neurons are affected through:
- Basal ganglia circuitry: Altered glutamatergic signaling in the direct and indirect pathways
- Dopaminergic degeneration: mGluR3 may modulate vulnerability of dopaminergic neurons
- Levodopa-induced dyskinesia: Group II mGluRs implicated in dyskinesia pathophysiology
- Motor neuron vulnerability: Altered expression of GRM3 in spinal motor neurons
- Glial-neuronal interactions: mGluR3 on astrocytes modulates glutamate clearance
- Excitotoxicity: Dysregulated glutamate signaling contributes to motor neuron death
¶ Schizophrenia and Psychiatric Disorders
While not primarily a neurodegenerative condition, GRM3 genetic variants are associated with:
- Schizophrenia risk
- Cognitive deficits
- Treatment response to antipsychotics
GRM3 represents a promising therapeutic target:
- Positive allosteric modulators (PAMs): Enhance mGluR3 signaling for neuroprotection
- Negative allosteric modulators (NAMs): Reduce excitotoxicity in acute settings
- Dual GRM2/3 agonists: Modulate glutamate transmission
¶ Clinical Candidates
Several compounds targeting group II mGluRs have been investigated:
- LY341495: Broad mGluR antagonist used in research
- MPEP derivatives: mGluR5 ligands with neuroprotective properties
- Azinphyl: Experimental GRM3-selective compounds
GRM3 knockout mice exhibit:
- Enhanced hippocampal LTP
- Aligned stress responses
- Modified locomotor activity
- Cognitive phenotypes under investigation
Mouse models with neuronal GRM3 overexpression show:
- Altered glutamatergic synaptic transmission
- Modified anxiety-like behaviors
- Neuroprotection in some paradigms
- Corti F, et al. (2002). Metabotropic glutamate receptors: beyond the canonical family. Current Drug Targets.
- Niswender CM, Conn PJ. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology.
- Marek GJ, et al. (2010). Metabotropic glutamate mGlu3 as a target for novel antidepressant drugs. Neuropharmacology.
- Benneyworth MA, et al. (2011). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a late-phase LTP in hippocampal area CA1. Neuropharmacology.
- Joffe ME, et al. (2019). mGlu3 and mGlu5 metabotropic glutamate receptors co-localize and interact in corticostriatal astrocytes. Glia.
- Lyon L, et al. (2021). Group II metabotropic glutamate receptors in neurodegeneration: new targets for neuroprotection. Neurobiology of Disease.
- Takao K, et al. (2022). GRM3 deficiency leads to enhanced amyloid-beta pathology in mouse models. Journal of Alzheimer's Disease.
- Zhang Y, et al. (2023). Astrocytic mGluR3 regulates synaptic transmission and cognitive function in Alzheimer's disease. Cell Reports.